The recent renaming of Polycystic Ovary Syndrome (PCOS) to Polyendocrine Metabolic Ovary Syndrome (PMOS) is a significant development in medical terminology, reflecting a decade-long effort to improve patient care and understanding. This change, driven by patient advocacy and a collaborative team of health professionals, marks a pivotal moment in how we approach and manage this complex condition. In my opinion, the renaming process and its implications are not just about changing a label, but about transforming the way we perceive and treat a disease that affects millions of women worldwide. Let's delve into the story behind this change, its impact, and what it means for the future of PMOS care.
The Need for a New Name
For years, PCOS has been a confusing and misleading term. The average time to diagnosis is over a year, and many patients struggle to find the right care due to the condition's multifaceted nature. The old name, PCOS, overemphasized the role of the ovaries, leading to a delayed diagnosis and fragmented care. In my view, this was a critical issue, as the condition affects many body systems, including hormones, metabolism, mental health, skin, and the reproductive system. The signs and symptoms often start in the teenage years and continue after menopause, making it a complex and often misunderstood disease.
What makes this particularly fascinating is the impact of a name on diagnosis and treatment. The previous name, PCOS, contributed to a delayed diagnosis and stigma, as many patients didn't recognize the condition's signs and symptoms. This led to a fragmented care experience, with patients often visiting multiple providers without finding the right treatment. The renaming process aimed to address these issues by creating a more accurate and inclusive term that better reflects the condition's true nature.
The Renaming Process
The journey to PMOS began with a global call from patients and health professionals in 2015. Over the next decade, an international team of experts, including myself, discussed and refined the new name. The process involved two rounds of global surveys, gathering insights from over 14,000 participants across various regions and disciplines. The surveys revealed a strong desire for a change, with 86% of patients and health professionals supporting the move.
One thing that immediately stands out is the importance of inclusivity and thoroughness in renaming a disease. The team prioritized scientific and medical accuracy, clarity, ease of pronunciation, avoiding stigma, and cultural appropriateness. The majority preferred an updated name that reflected the endocrine, metabolic, and ovarian features of the condition, rather than retaining the existing acronym or adopting a generic term. This inclusive approach ensured that the new name was shaped by the people who live with the condition and those who care for them.
The Impact of PMOS
The new name, PMOS, is clearer and more accurate, better reflecting the condition's true nature. It acknowledges the multifaceted impact of the disease on various body systems, which is crucial for improving diagnosis and treatment. In my perspective, the renaming process has already started to change care by raising awareness and encouraging specialists to better diagnose, study, and treat PMOS.
What many people don't realize is the significant impact of PMOS on metabolic health. The condition is associated with higher insulin levels, contributing to worse metabolic disease, including Type 2 diabetes, high cholesterol, high blood pressure, excess liver fat, weight gain, and obstructive sleep apnea. A 2025 study found that over 45% of women with PMOS had a metabolic disease diagnosis, compared to around 25% of those without PMOS. This highlights the importance of early diagnosis and management to prevent or treat these related conditions.
The Future of PMOS Care
Over the next three years, our team will be working to help patients, health professionals, governments, and researchers around the world transition from using PCOS to PMOS. The new name will be included in the 2028 update to the international guideline on the condition. This transition is crucial for ensuring that patients receive the best possible care and that healthcare professionals have the most accurate and up-to-date information.
From my perspective, the renaming of PCOS to PMOS is a significant step forward in patient advocacy and medical terminology. It reflects a decade-long effort to improve care and understanding of a complex condition that affects millions of women. The new name, PMOS, is a clearer and more accurate representation of the disease, and it will help to improve diagnosis, treatment, and patient outcomes. The continued advocacy of patients and health professionals will be instrumental in ensuring that PMOS is recognized and managed effectively, leading to a brighter and healthier future for those affected by this condition.
